Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vaccine Innovators Convene to Discuss New Technologies

Published: Monday, March 18, 2013
Last Updated: Monday, March 18, 2013
Bookmark and Share
New technologies to produce vaccines more safely, quickly and economically than traditional approaches are featured at the New Cells, New Vaccines VII: From Protein to Product international scientific conference.

Keynote Speaker Dr. Robin Robinson, Deputy Assistant Secretary and Director Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, will lead off the three-day conference with a presentation titled “Flexible Manufacturing & Synthetic Biology Converge Towards New Defense against Threats.”

Leading scientists, business leaders and regulatory agency representatives from around the world are gathered for the scientific conference to exchange information on bringing life-saving vaccines and antibodies to market more quickly through innovative manufacturing processes. At the conference, world-leading scientists will share how these advances significantly impact responsiveness to life-threatening infectious disease epidemics and bioterrorism threats.

The event is hosted by plant-based vaccine production pioneer, Fraunhofer USA Center for Molecular Biotechnology (CMB), located at the Delaware Technology Park in Newark, Delaware, and is conducted in cooperation with the International Association for Biological Standardization (IABS), headquartered in Geneva, Switzerland.

New Advances in Vaccine Production Proven Safe, Efficient and Effective

With the growing global demand for vaccines and other biologics, development of new, alternative production technologies is critical. The latest advancements in protein production include the use of stem cell, insect cell and plant systems.

“Through the conference,” Executive Director, Fraunhofer USA Center for Molecular Biotechnology and member of the conference organizing committee Dr. Yusibov said, “we hope to exchange information about the progress made by these new technologies in the past several years and spur collaboration for additional discoveries among representatives from academic research and the biotechnology and pharmaceutical industries.”

With a focus on getting to market, topics to be discussed during the three-day conference include progress through clinical trials, technology transfer, and regulatory considerations for new technologies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!